News

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

AffyImmune Therapeutics announced FDA approval of their investigational new drug (IND) for AIC100, a CAR-T cell therapy aimed at treating patients with advanced thyroid cancer. The first-in-human phase I study will be sponsored by Weill Cornell Medical Center. Yourway is anticipating a surge in clinical trials exploring these advanced therapies, and is prepared to support any customers for their unique needs.

Back to Index
Media

Upcoming Event

Clinical Trial Supply Europe

March 11-12, 2020
Madrid, Spain
Booth #54

Media

Articles

Agility and Flexibility in a Company That Provides Both Courier and Clinical Packaging Services